{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:15:01Z","timestamp":1777670101649,"version":"3.51.4"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>Hepatitis B virus (HBV) infection and chronic kidney disease (CKD) pose major global health challenges. CKD patients face a heightened risk of HBV infection, worsening their prognosis. This study evaluated the immune response to hepatitis B vaccination in CKD patients, the persistence of antibodies, and factors influencing vaccine efficacy. A retrospective study was conducted on 173 CKD patients (2014\u20132019) receiving routine vaccination at the Hospital Cl\u00ednico Universitario de Valladolid, Spain. (ZIP Code:47003) Patients were immunized with Fendrix<jats:sup>\u00ae<\/jats:sup> on a 0-1-2-6-month schedule, and verbal informed consent was obtained. A protective response was defined as Anti-HBs &amp;gt;10\u202fIU\/L, and a robust response as &amp;gt;100\u202fIU\/L. Overall, 90.8% achieved a protective response. Age was not a significant predictor (<jats:italic>p<\/jats:italic> =\u202f0.137) between non-responders and protective or robust responders. 32.95% of patients died during follow-up. A robust response at the end of vaccination cycle was associated with higher antibody titers at 12\u202fmonths (<jats:italic>p<\/jats:italic> =\u202f0.002) but not at 24 (<jats:italic>p<\/jats:italic> =\u202f0.550) or 36\u202fmonths (<jats:italic>p<\/jats:italic> =\u202f0.739). Kaplan\u2013Meier analysis estimated median antibody duration as 26.5\u202fmonths (Anti-HBs\u202f&amp;gt;\u202f10\u202fIU\/L) and 25.4\u202fmonths (Anti-HBs\u202f&amp;gt;\u202f100\u202fIU\/L). A delay in vaccination compared to the recommended schedule was observed (one-sample Wilcoxon test, <jats:italic>p<\/jats:italic> &amp;lt;\u202f0.001). Fendrix<jats:sup>\u00ae<\/jats:sup> effectively induces protective immunity in CKD patients, but a robust early response does not ensure long-term persistence. The decline in antibody levels suggests the need for booster doses and periodic antibody monitoring to optimize long-term protection. Suboptimal vaccination adherence may reflect the inherent complexities of real-world clinical practice.<\/jats:p>","DOI":"10.3389\/fpubh.2025.1523733","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T23:04:09Z","timestamp":1743116649000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunogenicity and predictive factors of hepatitis B vaccination with Fendrix\u00ae in chronic kidney disease patients"],"prefix":"10.3389","volume":"13","author":[{"given":"Cristina","family":"Hern\u00e1n-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Leonardo","family":"S\u00e1nchez-Carmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda Czestochowa","family":"Mateo-Otero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Fern\u00e1ndez-Espinilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula Andrea","family":"Rodriguez-Ducuara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Javier","family":"Castrodeza-Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camino","family":"Prada-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"ref1","first-page":"1","volume-title":"Global hepatitis report 2024: Action for access in low- and middle-income countries","year":"2024"},{"key":"ref2","article-title":"las hepatitis v\u00edricas y las infecciones de transmisi\u00f3n sexual para el periodo 2022\u20132030","year":"2022"},{"key":"ref3","article-title":"Hepatitis B. Manual de inmunizaciones en l\u00ednea de la AEP","year":"2015"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s10157-018-1676-x","article-title":"Factors affecting inadequate response to HBV vaccine in hemodialysis patients: northeast anatolia survey with six hemodialysis centers","volume":"23","author":"Erdo\u011fdu","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s11255-017-1616-9","article-title":"Factors affecting responsiveness to hepatitis B immunization in dialysis patients","volume":"49","author":"Asan","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"ref6","article-title":"\u00c1reas - Salud p\u00fablica - Prevenci\u00f3n de la salud - Vacunaciones - Programa vacunaci\u00f3n - Condiciones de riesgo","year":"2020"},{"key":"ref7","year":"2018"},{"key":"ref8","article-title":"sempspgs.es","year":"2012"},{"key":"ref9","article-title":"European medicines agency","year":"2009"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/ki.2008.57","article-title":"Hepatitis B in chronic kidney disease: moving toward effective prevention","volume":"73","author":"Unger","year":"2008","journal-title":"Kidney Int"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.4161\/hv.7.9.16225","article-title":"Anti-HBs antibody persistence following primary vaccination with an investigational AS02v-adjuvanted hepatitis B vaccine in patients with renal insufficiency","volume":"7","author":"Surquin","year":"2011","journal-title":"Hum Vaccin"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1111\/j.1523-1755.2005.00689.x","article-title":"Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients","volume":"68","author":"Chiew Tong","year":"2005","journal-title":"Kidney Int"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.clinre.2019.06.010","article-title":"HBV vaccination with Fendrix is effective and safe in pre-dialysis CKD population","volume":"44","author":"Fabrizi","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref14","year":"2017"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0140-6736(99)07239-6","article-title":"Are booster immunisations needed for lifelong hepatitis B immunity?","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/011874303X304324240529133609","article-title":"Comparison of factors affecting the immune response to hepatitis B vaccination in patients with stage 5 chronic kidney disease-haemodialysis and Predialysis","volume":"17","author":"Light","year":"2024","journal-title":"Open Urol Nephrol J"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"882","DOI":"10.4067\/S0034-98872012000700008","article-title":"Respuesta inmunitaria a la vacuna de la hepatitis B en pacientes hemodializados en Brasil y sus factores asociados","volume":"140","author":"Pereira","year":"2012","journal-title":"Rev Med Chil"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3265\/Nefrologia.2009.29.5.5349.en.full","article-title":"Long-term evaluation of inmune response to hepatitis B vaccine in 136 patients undergoing hemodialysis","volume":"29","author":"Pin","year":"2009","journal-title":"Nefrolog\u00eda"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1159\/000368534","article-title":"Recombinant hepatitis B vaccine Adjuvanted with AS04 in Dialysis patients: a prospective cohort study","volume":"40","author":"Fabrizi","year":"2015","journal-title":"Kidney Blood Press Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1586\/14760584.6.2.133","article-title":"New hepatitis B vaccine formulated with an improved adjuvant system","volume":"6","author":"Kundi","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1517\/14712598.8.2.235","article-title":"Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients","volume":"8","author":"Beran","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.nefro.2018.04.004","article-title":"Prevalencia de enfermedad renal cr\u00f3nica en Espa\u00f1a: impacto de la acumulaci\u00f3n de factores de riesgo cardiovascular","volume":"38","author":"Gorostidi","year":"2018","journal-title":"Nefrologia"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.3346\/jkms.2018.33.e264","article-title":"Chronic hepatitis B infection is significantly associated with chronic kidney disease: a population-based, matched case-control study","volume":"33","author":"Kim","year":"2018","journal-title":"J Korean Med Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3748\/wjg.v19.i9.1349","article-title":"Efficacy of the vaccination in inflammatory bowel disease","volume":"19","author":"Carrera","year":"2013","journal-title":"World J Gastroenterol"},{"key":"ref25","article-title":"Timing and spacing of Immunobiologics","year":"2024"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1523733\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T23:04:13Z","timestamp":1743116653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1523733\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":25,"alternative-id":["10.3389\/fpubh.2025.1523733"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1523733","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"article-number":"1523733"}}